JP6122877B2 - ユビキチン活性化酵素のピラゾロピリミジニル阻害剤 - Google Patents

ユビキチン活性化酵素のピラゾロピリミジニル阻害剤 Download PDF

Info

Publication number
JP6122877B2
JP6122877B2 JP2014557765A JP2014557765A JP6122877B2 JP 6122877 B2 JP6122877 B2 JP 6122877B2 JP 2014557765 A JP2014557765 A JP 2014557765A JP 2014557765 A JP2014557765 A JP 2014557765A JP 6122877 B2 JP6122877 B2 JP 6122877B2
Authority
JP
Japan
Prior art keywords
halo
aliphatic
compound
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014557765A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015508775A (ja
JP2015508775A5 (OSRAM
Inventor
ローシャン アフローゼ,
ローシャン アフローゼ,
インドゥ ティー. バラサン,
インドゥ ティー. バラサン,
ジェフェリー ピー. チャバリ,
ジェフェリー ピー. チャバリ,
ポール イー. フレミング,
ポール イー. フレミング,
ジェフェリー エル. ゴーリン,
ジェフェリー エル. ゴーリン,
マリオ ジラード,
マリオ ジラード,
スティーブン ピー. ラングストン,
スティーブン ピー. ラングストン,
フランソワ アール. ソーシー,
フランソワ アール. ソーシー,
ツ−チン ウォン,
ツ−チン ウォン,
インチュン イエ,
インチュン イエ,
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of JP2015508775A publication Critical patent/JP2015508775A/ja
Publication of JP2015508775A5 publication Critical patent/JP2015508775A5/ja
Application granted granted Critical
Publication of JP6122877B2 publication Critical patent/JP6122877B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2014557765A 2012-02-17 2013-02-14 ユビキチン活性化酵素のピラゾロピリミジニル阻害剤 Active JP6122877B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261600070P 2012-02-17 2012-02-17
US61/600,070 2012-02-17
PCT/US2013/026113 WO2013123169A1 (en) 2012-02-17 2013-02-14 Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme

Publications (3)

Publication Number Publication Date
JP2015508775A JP2015508775A (ja) 2015-03-23
JP2015508775A5 JP2015508775A5 (OSRAM) 2017-03-16
JP6122877B2 true JP6122877B2 (ja) 2017-04-26

Family

ID=48982730

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014557765A Active JP6122877B2 (ja) 2012-02-17 2013-02-14 ユビキチン活性化酵素のピラゾロピリミジニル阻害剤

Country Status (30)

Country Link
US (4) US9290500B2 (OSRAM)
EP (3) EP3173413B1 (OSRAM)
JP (1) JP6122877B2 (OSRAM)
KR (1) KR20140123104A (OSRAM)
CN (1) CN104136399B (OSRAM)
AR (1) AR092797A1 (OSRAM)
BR (1) BR112014020365B1 (OSRAM)
CA (1) CA2864672C (OSRAM)
CL (1) CL2014002181A1 (OSRAM)
CO (1) CO7071135A2 (OSRAM)
CR (1) CR20140380A (OSRAM)
DO (1) DOP2014000187A (OSRAM)
EA (1) EA035020B1 (OSRAM)
EC (1) ECSP14019113A (OSRAM)
ES (1) ES2739150T3 (OSRAM)
GE (1) GEP201706687B (OSRAM)
HK (1) HK1201817A1 (OSRAM)
IL (1) IL234016A0 (OSRAM)
MA (1) MA35932B1 (OSRAM)
MX (1) MX352963B (OSRAM)
NZ (1) NZ628969A (OSRAM)
PE (1) PE20142244A1 (OSRAM)
PH (1) PH12014501832A1 (OSRAM)
SG (2) SG10201606581RA (OSRAM)
TN (1) TN2014000351A1 (OSRAM)
TW (1) TWI593688B (OSRAM)
UA (1) UA116534C2 (OSRAM)
UY (1) UY34629A (OSRAM)
WO (1) WO2013123169A1 (OSRAM)
ZA (1) ZA201406103B (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008307B2 (en) 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
KR20140123104A (ko) 2012-02-17 2014-10-21 밀레니엄 파머슈티컬스 인코퍼레이티드 유비퀴틴 활성화 효소의 피라졸로피리미디닐 억제제
WO2014022744A1 (en) 2012-08-03 2014-02-06 Millennium Pharmaceuticals, Inc. INDOLE-SUBSTITUTED PYRROLOPYRIMIDINYL INHIBITORS OF Uba6
EP3016934B1 (en) 2013-07-02 2018-01-10 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of sumo activating enzyme
JP6603712B2 (ja) 2014-07-01 2019-11-06 ミレニアム ファーマシューティカルズ, インコーポレイテッド Sumo活性化酵素の阻害薬として有用なヘテロアリール化合物
WO2016069393A1 (en) 2014-10-29 2016-05-06 Millennium Pharmaceuticals, Inc. Administration of ubiquitin-activating enzyme inhibitor and radiation
US20180133221A1 (en) 2014-10-29 2018-05-17 Millennium Pharmaceuticals, Inc. Administration of ubiquitin-activating enzyme inhibitor and chemotherapeutic agents
AU2019370200B2 (en) 2018-10-30 2024-12-19 Kronos Bio, Inc. Compounds, compositions, and methods for modulating CDK9 activity
WO2023021498A1 (en) * 2021-08-16 2023-02-23 Moya Bio Ltd. Fused azole and furan based nucleoside analogs and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040023901A1 (en) 2002-02-28 2004-02-05 Cook Phillip D. Nucleoside 5'-monophosphate mimics and their prodrugs
JP2006501260A (ja) 2002-09-04 2006-01-12 シェーリング コーポレイション サイクリン依存性キナーゼインヒビターとしてのピラゾロピリミジン
US7067661B2 (en) 2002-09-04 2006-06-27 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7563798B2 (en) 2002-09-04 2009-07-21 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
US7196092B2 (en) 2002-09-04 2007-03-27 Schering Corporation N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors
WO2004087707A1 (en) 2003-03-31 2004-10-14 Vernalis (Cambridge) Limited Pyrazolopyrimidine compounds and their use in medicine
JP2005008581A (ja) 2003-06-20 2005-01-13 Kissei Pharmaceut Co Ltd 新規なピラゾロ[1,5−a]ピリミジン誘導体、それを含有する医薬組成物およびそれらの用途
US20050130974A1 (en) 2003-10-17 2005-06-16 Rigel Pharmaceuticals, Inc. Benzothiazole compositions and their use as ubiquitin ligase inhibitors
EP1758873A1 (en) 2004-06-22 2007-03-07 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
WO2006084281A1 (en) 2005-02-04 2006-08-10 Millennium Pharmaceuticals, Inc. Inhibitors of e1 activating enzymes
WO2007044426A2 (en) 2005-10-06 2007-04-19 Schering Corporation Pyrazolopyrimidines as protein kinase inhibitors
DK1989206T3 (da) 2006-02-02 2012-10-08 Millennium Pharm Inc E1-aktiveringsenzymhæmmere
US8147618B2 (en) * 2006-02-28 2012-04-03 Lam Research Ag Device and method for liquid treating disc-like articles
MY157177A (en) 2006-08-08 2016-05-13 Millennium Pharm Inc Heteroaryl compounds useful as inhibitors of e1 activating enzymes
US8008307B2 (en) 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
CA2691987C (en) 2007-06-12 2016-08-16 Achaogen, Inc. Antibacterial agents
ES2757928T3 (es) 2007-08-02 2020-04-30 Millennium Pharm Inc Proceso para la síntesis de inhibidores de enzimas activadoras E1
WO2009082691A1 (en) 2007-12-21 2009-07-02 Board Of Regents, University Of Texas System Dihydroorotate dehydrogenase inhibitors with selective anti-malarial activity
WO2010086040A1 (en) 2009-01-29 2010-08-05 Biomarin Iga, Ltd. Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy
WO2010088518A2 (en) 2009-01-31 2010-08-05 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
NZ596470A (en) 2009-05-14 2014-04-30 Millennium Pharm Inc Hydrochloride salt of ((1s,2s,4r)-4-{ 4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl} -2-hydroxycyclopentyl)methyl sulfamate
WO2011109059A1 (en) 2010-03-01 2011-09-09 Gtx, Inc. Compounds for treatment of cancer
US20120077814A1 (en) 2010-09-10 2012-03-29 Zhong Wang Sulfonamide, sulfamate, and sulfamothioate derivatives
CA2846231C (en) 2011-08-24 2017-06-20 Millennium Pharmaceuticals, Inc. Inhibitors of nedd8-activating enzyme
KR20140123104A (ko) 2012-02-17 2014-10-21 밀레니엄 파머슈티컬스 인코퍼레이티드 유비퀴틴 활성화 효소의 피라졸로피리미디닐 억제제
WO2014022744A1 (en) 2012-08-03 2014-02-06 Millennium Pharmaceuticals, Inc. INDOLE-SUBSTITUTED PYRROLOPYRIMIDINYL INHIBITORS OF Uba6
EP3016934B1 (en) 2013-07-02 2018-01-10 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of sumo activating enzyme
JP6603712B2 (ja) 2014-07-01 2019-11-06 ミレニアム ファーマシューティカルズ, インコーポレイテッド Sumo活性化酵素の阻害薬として有用なヘテロアリール化合物

Also Published As

Publication number Publication date
KR20140123104A (ko) 2014-10-21
CO7071135A2 (es) 2014-09-30
TN2014000351A1 (en) 2015-12-21
EP3173413A1 (en) 2017-05-31
MA35932B1 (fr) 2014-12-01
ES2739150T3 (es) 2020-01-29
CA2864672A1 (en) 2013-08-22
BR112014020365B1 (pt) 2023-02-23
MX352963B (es) 2017-12-15
CA2864672C (en) 2018-01-09
US9290500B2 (en) 2016-03-22
EP3536692A1 (en) 2019-09-11
EP2814791A4 (en) 2015-08-19
CN104136399B (zh) 2018-08-07
US20130217682A1 (en) 2013-08-22
US9663525B2 (en) 2017-05-30
SG10201606581RA (en) 2016-09-29
US20140088096A9 (en) 2014-03-27
CR20140380A (es) 2014-10-28
US10202389B2 (en) 2019-02-12
EP3173413B1 (en) 2019-05-01
US20170217968A1 (en) 2017-08-03
GEP201706687B (en) 2017-06-26
UA116534C2 (uk) 2018-04-10
TW201345909A (zh) 2013-11-16
MX2014009944A (es) 2014-11-10
ECSP14019113A (es) 2015-09-30
DOP2014000187A (es) 2014-10-15
US20160244455A1 (en) 2016-08-25
JP2015508775A (ja) 2015-03-23
EP3536692B1 (en) 2021-04-07
UY34629A (es) 2013-09-02
EP2814791A1 (en) 2014-12-24
EA201400831A1 (ru) 2014-12-30
HK1201817A1 (en) 2015-09-11
PH12014501832A1 (en) 2014-11-17
SG11201404757WA (en) 2014-09-26
US9796725B2 (en) 2017-10-24
BR112014020365A2 (pt) 2020-12-22
US20170369499A1 (en) 2017-12-28
WO2013123169A1 (en) 2013-08-22
TWI593688B (zh) 2017-08-01
PE20142244A1 (es) 2015-01-07
AR092797A1 (es) 2015-05-06
CN104136399A (zh) 2014-11-05
CL2014002181A1 (es) 2014-12-12
IL234016A0 (en) 2014-09-30
ZA201406103B (en) 2017-11-29
NZ628969A (en) 2017-03-31
EA035020B1 (ru) 2020-04-17

Similar Documents

Publication Publication Date Title
JP6122877B2 (ja) ユビキチン活性化酵素のピラゾロピリミジニル阻害剤
TWI798635B (zh) 吡啶並嘧啶酮類化合物及其應用
JP2015508775A5 (OSRAM)
EP2382207B1 (en) Pi3k/mtor kinase inhibitors
JP2022078315A (ja) Mk2阻害剤およびその使用
TWI580679B (zh) 雜芳基並嘧啶類衍生物、其製備方法和用途
EP2483272A2 (en) Pi3k (delta) selective inhibitors
EP3398947A1 (en) Nitrogen-containing fused heterocyclic compound, as well as preparation method, intermediate, composition and application thereof
JP6118890B2 (ja) 癌の治療のための6−(4−(1−アミノ−3−ヒドロキシシクロブチル)フェニル)−5−フェニル−(フロ、チエノ、又はピロロ)[2,3−d]ピリミジン−4−オン誘導体
JP2022119853A (ja) キナゾリン化合物並びにその調製方法、使用及び医薬組成物
TW202509040A (zh) 三環類化合物及其用途
CN114369097B (zh) 杂芳环类AhR抑制剂
HK1238244A1 (en) Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
HK1222388B (en) Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
HK1222388A1 (en) Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160212

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160212

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160818

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160913

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161208

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20170210

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170303

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170403

R150 Certificate of patent or registration of utility model

Ref document number: 6122877

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250